Literature DB >> 16870257

Pathogenic role of anti-C1q autoantibodies in the development of lupus nephritis--a hypothesis.

Roelof Flierman1, Mohamed R Daha.   

Abstract

A substantial proportion of patients with systemic lupus erythematosus (SLE) develop renal inflammatory disease, so-called lupus nephritis (LN). LN is a severe complication of SLE which is strongly associated with the presence of autoantibodies against C1q, the first component of the complement system, and other self-antigens (i.e. against DNA and nucleosomes) as well. In this review, the authors focus on anti-C1q autoantibodies and interpret the available data in order to explain how LN may develop and how anti-C1q autoantibodies contribute to its pathogenesis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16870257     DOI： 10.1016/j.molimm.2006.06.010

Source DB:  PubMed          Journal:  Mol Immunol        ISSN： 0161-5890            Impact factor:   4.407


  10 in total

Review 1.  T cells and autoimmune kidney disease.

Authors:  Abel Suárez-Fueyo; Sean J Bradley; David Klatzmann; George C Tsokos
Journal:  Nat Rev Nephrol       Date:  2017-03-13       Impact factor: 28.314

Review 2.  Are anti-C1q antibodies different from other SLE autoantibodies?

Authors:  Matthew C Pickering; Marina Botto
Journal:  Nat Rev Rheumatol       Date:  2010-04-27       Impact factor: 20.543

3.  Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity.

Authors:  Sladjana Andrejevic; Ivica Jeremic; Mirjana Sefik-Bukilica; Milos Nikolic; Biljana Stojimirovic; Branka Bonaci-Nikolic
Journal:  Clin Rheumatol       Date:  2013-07-16       Impact factor: 2.980

4.  Anti-C1q antibodies: association with nephritis and disease activity in systemic lupus erythematosus.

Authors:  Carlos Geraldo Moura; Isabella Lima; Lúcio Barbosa; Daniel Athanazio; Eliana Reis; Mitermayer Reis; Rufus W Burlingame; Mittermayer B Santiago
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 5.  Current status and issues of C1q nephropathy.

Authors:  Akiko Mii; Akira Shimizu; Yukinari Masuda; Emiko Fujita; Kaoru Aki; Masamichi Ishizaki; Shigeru Sato; Adam Griesemer; Yuh Fukuda
Journal:  Clin Exp Nephrol       Date:  2009-04-17       Impact factor: 2.801

6.  Autoantibodies against complement C1q correlate with the thyroid function in patients with autoimmune thyroid disease.

Authors:  E Potlukova; J Jiskra; Z Limanova; P Kralikova; D Smutek; H Mareckova; M Antosova; M Trendelenburg
Journal:  Clin Exp Immunol       Date:  2008-05-23       Impact factor: 4.330

7.  Interaction of HmC1q with leech microglial cells: involvement of C1qBP-related molecule in the induction of cell chemotaxis.

Authors:  Muriel Tahtouh; Annelise Garçon-Bocquet; Françoise Croq; Jacopo Vizioli; Pierre-Eric Sautière; Christelle Van Camp; Michel Salzet; Patricia Nagnan-le Meillour; Joël Pestel; Christophe Lefebvre
Journal:  J Neuroinflammation       Date:  2012-02-22       Impact factor: 8.322

8.  Anti-C1q autoantibodies from systemic lupus erythematosus patients enhance CD40-CD154-mediated inflammation in peripheral blood mononuclear cells in vitro.

Authors:  Pascal Alexander Rabatscher; Marten Trendelenburg
Journal:  Clin Transl Immunology       Date:  2022-08-02

9.  Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus.

Authors:  Olivier C Meyer; Pascale Nicaise-Roland; Nolwenn Cadoudal; Sabine Grootenboer-Mignot; Elisabeth Palazzo; Gilles Hayem; Philippe Dieudé; Sylvie Chollet-Martin
Journal:  Arthritis Res Ther       Date:  2009-06-10       Impact factor: 5.156

10.  Interleukin-15 (IL-15) and anti-C1q antibodies as serum biomarkers for ectopic pregnancy and missed abortion.

Authors:  Alexandros Daponte; Efthimios Deligeoroglou; Spyros Pournaras; Christos Hadjichristodoulou; Antonios Garas; Foteini Anastasiadou; Ioannis E Messinis
Journal:  Clin Dev Immunol       Date:  2013-01-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.